

Uwe K Zettl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5433792/publications.pdf>

Version: 2024-02-01

77
papers

2,503
citations

236925

25
h-index

223800

46
g-index

77
all docs

77
docs citations

77
times ranked

4066
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease-modifying therapies and infectious risks in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2016, 12, 217-233.	10.1	199
2	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	6.0	173
3	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	10.3	133
4	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	1.9	123
5	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	7.6	115
6	Multiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration. <i>Autoimmunity Reviews</i> , 2016, 15, 210-220.	5.8	105
7	Immune-mediated CNS diseases: A review on nosological classification and clinical features. <i>Autoimmunity Reviews</i> , 2012, 11, 167-173.	5.8	93
8	NLRP3 inflammasome is associated with the response to IFN- γ in patients with multiple sclerosis. <i>Brain</i> , 2015, 138, 644-652.	7.6	93
9	Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 483-498.	1.8	71
10	Vaccination in Multiple Sclerosis: Friend or Foe?. <i>Frontiers in Immunology</i> , 2019, 10, 1883.	4.8	70
11	Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions. <i>Autoimmunity Reviews</i> , 2017, 16, 925-936.	5.8	68
12	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	6.1	67
13	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 681-686.	1.9	66
14	Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. <i>CNS Drugs</i> , 2017, 31, 33-50.	5.9	57
15	Treatment choices and neuropsychological symptoms of a large cohort of early MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e446.	6.0	54
16	Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases. <i>Journal of Immunology</i> , 2019, 202, 2177-2187.	0.8	53
17	Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 9-30.	3.5	51
18	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 841.	9.0	48

#	ARTICLE	IF	CITATIONS
19	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German "Austrian retrospective multicenter study in patients with a clinically isolated syndrome. <i>Journal of Neurology</i> , 2016, 263, 2499-2504.	3.6	46
20	Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions. , 1999, 28, 34-39.		44
21	Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients. <i>PLoS ONE</i> , 2015, 10, e0134583.	2.5	41
22	Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing "remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1202-1214.	3.0	40
23	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	38
24	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015, 52, 848-855.	3.2	34
25	Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine "phosphate receptor modulator. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 193-201.	3.9	32
26	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. <i>Pain</i> , 2020, 161, 787-796.	4.2	29
27	Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1888-1890.	3.0	28
28	Vaccination and immunotherapies in neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2022, 18, 289-306.	10.1	27
29	Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102485.	2.0	26
30	Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1033-1043.	1.9	26
31	Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). <i>European Journal of Health Economics</i> , 2014, 15, 953-966.	2.8	24
32	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , 2019, 266, 386-397.	3.6	24
33	Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2020, 33, 286-294.	3.6	23
34	Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis " an observational study. <i>European Journal of Clinical Investigation</i> , 2015, 45, 587-593.	3.4	17
35	Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. <i>EBioMedicine</i> , 2020, 56, 102822.	6.1	17
36	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 192-202.	5.3	17

#	ARTICLE	IF	CITATIONS
37	Coping behavior in multiple sclerosis“complementary and alternative medicine: A cross“sectional study. CNS Neuroscience and Therapeutics, 2018, 24, 784-789.	3.9	16
38	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. Genetic Epidemiology, 2015, 39, 601-608.	1.3	15
39	Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis. Journal of Neuroimmunology, 2015, 278, 277-279.	2.3	15
40	Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure?. Movement Disorders, 2000, 15, 1279-1281.	3.9	14
41	Oxides and apoptosis in inflammatory myopathies. Microscopy Research and Technique, 2001, 55, 249-258.	2.2	14
42	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody“Associated Disease. Neurology, 2022, 98, .	1.1	14
43	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3: Genes, Genomes, Genetics, 2016, 6, 2073-2079.	1.8	13
44	Headache at the Time of First Symptom Manifestation of Multiple Sclerosis: A Prospective, Longitudinal Study. European Neurology, 2018, 80, 115-120.	1.4	13
45	Association of smoking but not HLA-DRB1*15:01, <i>APOE</i> or body mass index with brain atrophy in early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 661-668.	3.0	12
46	Tick-borne encephalitis vaccination in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	12
47	Epilepsy as a predictor of disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 942-949.	3.0	12
48	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 1507-1510.	3.0	11
49	Headache in the course of multiple sclerosis: a prospective study. Journal of Neural Transmission, 2019, 126, 131-139.	2.8	11
50	Is APOE Îµ4 associated with cognitive performance in early MS?. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e728.	6.0	11
51	Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	3.5	11
52	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 497-498.	10.2	10
53	Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Current Pharmaceutical Design, 2022, 28, 428-436.	1.9	10
54	A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies. Brain, 2023, 146, 977-990.	7.6	10

#	ARTICLE	IF	CITATIONS
55	Cell-specific effects in different immune subsets associated with <i>SOCS1</i> genotypes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1498-1512.	3.0	8
56	Information processing deficits as a driving force for memory impairment in MS: A cross-sectional study of memory functions and MRI in early and late stage MS. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 119-127.	2.0	8
57	Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients. <i>Frontiers in Neurology</i> , 2020, 11, 996.	2.4	8
58	Aggressive multiple sclerosis: a matter of measurement and timing. <i>Brain</i> , 2020, 143, e97-e97.	7.6	8
59	Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry. <i>Multiple Sclerosis Journal</i> , 2022, 28, 865-871.	3.0	8
60	Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 173-174.	2.0	7
61	Genetic determinants of the humoral immune response in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, e827.	6.0	7
62	Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in Germany. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103534.	2.0	7
63	Progressive multifocal leukoencephalopathy in a patient with pre-clinical primary biliary cirrhosis. <i>Clinical Neurology and Neurosurgery</i> , 2014, 123, 45-49.	1.4	6
64	Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany – A registry-based/multicentric cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103281.	2.0	6
65	Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT. <i>Advances in Therapy</i> , 2022, 39, 2749-2760.	2.9	6
66	Predicting therapeutic efficacy of intravenous immunoglobulin (IVIg) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics. <i>Journal of Neuroimmunology</i> , 2014, 277, 145-152.	2.3	5
67	Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study. <i>Contemporary Clinical Trials Communications</i> , 2020, 18, 100574.	1.1	5
68	Editorial: Multiple Sclerosis – From Bench to Bedside: Currents Insights Into Pathophysiological Concepts and Their Potential Impact on Patients. <i>Frontiers in Immunology</i> , 2020, 11, 137.	4.8	4
69	Pioneers in neurology: Johannes Sayk (1923–2005). <i>Journal of Neurology</i> , 2009, 256, 2109-2110.	3.6	3
70	Dentate-nucleus gadolinium deposition on magnetic resonance imaging: ultrasonographic and clinical correlates in multiple sclerosis patients. <i>Neurological Sciences</i> , 2022, 43, 2631-2639.	1.9	3
71	Headache in multiple sclerosis - pharmacological aspects. <i>Current Pharmaceutical Design</i> , 2021, 27, .	1.9	2
72	Hans Queckenstedt (1876–1918). <i>Journal of Neurology</i> , 2017, 264, 1032-1034.	3.6	1

#	ARTICLE	IF	CITATIONS
73	A smart peek: Processing of rapid visual displays is disturbed in newly diagnosed, cognitively intact MS patients and refers to cognitive performance and disease progression in late stages. <i>Journal of the Neurological Sciences</i> , 2019, 401, 118-124.	0.6	1
74	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. <i>Cells</i> , 2020, 9, 175.	4.1	1
75	Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110225.	3.5	1
76	Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNS. <i>Current Pharmaceutical Design</i> , 2022, 28, 427-427.	1.9	1
77	Current Pharmaceutical Trends in Neuroimmunology – Part II: Autoimmunity Beyond the CNS and Other Disorders. <i>Current Pharmaceutical Design</i> , 2022, 28, 853-853.	1.9	1